ID   OV-MZ-1a
AC   CVCL_X962
SY   OVMZ-1a
DR   Wikidata; Q54936841
RX   PubMed=11242531;
RX   PubMed=15153938;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ile195Serfs*52 (c.582delT) (Leu194fs); ClinVar=VCV000634675; Zygosity=Unspecified (PubMed=15153938).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_X950 ! OV-MZ-1
SX   Female
AG   44Y
CA   Cancer cell line
DT   Created: 05-09-14; Last updated: 19-12-24; Version: 9
//
RX   PubMed=11242531; DOI=10.1089/10430340150504019;
RA   Bruning A., Kohler T., Quist S.R., Wang-Gohrke S., Mobus V.J.,
RA   Kreienberg R., Runnebaum I.B.;
RT   "Adenoviral transduction efficiency of ovarian cancer cells can be
RT   limited by loss of integrin beta3 subunit expression and increased by
RT   reconstitution of integrin alphaVbeta3.";
RL   Hum. Gene Ther. 12:391-399(2001).
//
RX   PubMed=15153938; DOI=10.1038/sj.cgt.7700727;
RA   Quist S.R., Wang-Gohrke S., Kohler T., Kreienberg R., Runnebaum I.B.;
RT   "Cooperative effect of adenoviral p53 gene therapy and standard
RT   chemotherapy in ovarian cancer cells independent of the endogenous p53
RT   status.";
RL   Cancer Gene Ther. 11:547-554(2004).
//